author-photo

Caroleen Quach

Genentech

5

Papers

28

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (9)
Patient-Reported Outcomes in a Phase 2 Study Comparing Atezolizumab Alone or With Bevacizumab Versus Sunitinib in Previously Untreated Metastatic Renal Cell Carcinoma.

2020 BJUI
Show All
- Source
- Cite
- Save
Citations (7)
Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
Integrating the patient (pt) voice with clinician reports to identify cancer-specific subsets of symptomatic adverse events (SymAE).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)